Nektar Therapeutics Reports Q1 2026 Financial Results Amid Class Action Concerns
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Nektar Therapeutics' stock fell 6.21% as it hit a 20-day low, reflecting investor concerns amid ongoing class action lawsuits.
The company reported significant cash growth, with cash and marketable securities totaling $731.6 million as of March 31, 2026, up from $245.8 million at the end of 2025. However, the ongoing class action lawsuits related to the failed REZOLVE-AA trial have raised serious concerns about the company's operational transparency and compliance, leading to a negative sentiment among investors. Despite the financial improvements, the legal challenges may overshadow the positive developments.
Investors are advised to closely monitor the situation as the class action lawsuits could impact Nektar's stock price and overall reputation. The company's commitment to R&D and clinical trials remains strong, but the legal issues present a significant risk that could affect future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 64.880
Low
102.00
Averages
123.43
High
165.00
Current: 64.880
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics to Participate in 2026 Healthcare Conference
- Conference Participation Announcement: Nektar Therapeutics announced its participation in the Jefferies Global Healthcare Conference from June 2-4, 2026, in New York, where management will webcast their session, likely increasing investor interest and enhancing the company's visibility in the biotech sector.
- Webcast Details: The conference webcast will be accessible via the investor events section of the company’s website, with a replay available for 30 days post-event, aimed at fostering investor engagement and enhancing transparency and trust.
- Product Development Progress: Nektar's lead candidate, REZPEG, is undergoing three clinical trials for atopic dermatitis, alopecia areata, and Type 1 diabetes, showcasing the company's potential in treating autoimmune and chronic inflammatory diseases, which may lay the groundwork for future market competitiveness.
- Pipeline Diversity: In addition to REZPEG, Nektar is developing several other candidates, including a preclinical TNFR2 antibody and bispecific programs, indicating a diversified strategy in biopharmaceuticals aimed at addressing the needs of various patient populations.
See More
Nektar to Present at 2026 Jefferies Global Healthcare Conference
- Conference Participation: Nektar Therapeutics will webcast its participation at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 1:20 p.m. Eastern Time, showcasing its latest advancements in treating autoimmune and chronic inflammatory diseases.
- Product Candidate Progress: Nektar's lead product candidate, rezpegaldesleukin (REZPEG), is undergoing three clinical trials, including Phase 2b studies for atopic dermatitis and Type 1 diabetes, highlighting the company's research potential in the biotechnology sector.
- Diverse Clinical Trials: In addition to REZPEG, Nektar is developing a range of candidates, including a bivalent tumor necrosis factor receptor type II antibody and bispecific programs, indicating a broad approach to treating various diseases.
- Investor Interaction Opportunities: During the conference, investors can request one-on-one meetings with company management through their respective representatives, enhancing communication and relationships with stakeholders.
See More
Prosight Management Increases Stake in Nektar Therapeutics
- Share Acquisition: On May 15, 2026, Prosight Management disclosed the purchase of 180,367 shares of Nektar Therapeutics, valued at approximately $10.27 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Prosight's stake in Nektar accounts for 8.67% of its 13F reportable AUM, highlighting its significance within the investment portfolio.
- Outstanding Stock Performance: As of May 14, 2026, Nektar's stock price stood at $66.61, having surged nearly 600% over the past year, significantly outperforming the S&P 500's 28% increase, reflecting market recognition of its potential.
- Strong Financial Position: Nektar reported first-quarter revenue of $10.9 million, with cash and marketable securities totaling $731.6 million, demonstrating relative strength among clinical-stage biotech peers and enhancing its funding capacity for future development.
See More
Prosight Management Increases Nektar Holdings by $10.27 Million
- Share Increase: Prosight Management increased its holdings in Nektar Therapeutics by 180,367 shares in Q1 2026, representing an estimated $10.27 million investment, reflecting confidence in the company's future.
- Asset Value Growth: The value of Nektar Therapeutics' position rose by $29.43 million during the quarter, driven by both stock price appreciation and the share addition, indicating the company's potential in the biotechnology sector.
- Strong Financial Position: Nektar's revenue increased from $10.5 million to $10.9 million in Q1, with cash and marketable securities totaling $731.6 million, showcasing its competitive edge among clinical-stage biotech firms.
- Clinical Development Outlook: Nektar's rezpegaldesleukin treatment has shown promising data in dermatological conditions, with plans to initiate Phase 3 trials by July, which could significantly enhance the company's valuation if successful.
See More
Prosight Management Increases Stake in Nektar Therapeutics
- Share Increase: On May 15, 2026, Prosight Management disclosed an increase of 180,367 shares in Nektar Therapeutics, valued at approximately $10.27 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The total value of Nektar's shares rose by $29.43 million at the end of the quarter, reflecting the dual impact of trading activity and share price appreciation, further solidifying Prosight's significance in its investment portfolio.
- Improved Financial Position: Nektar's revenue increased from $10.5 million to $10.9 million in the first quarter, with cash and marketable securities reaching $731.6 million, showcasing its relative strength among clinical-stage biotech peers.
- Clinical Development Outlook: Nektar's rezpegaldesleukin treatment has shown encouraging data in trials, with plans to initiate the Phase 3 ZENITH-AD program in July, which could significantly enhance the company's valuation if successful.
See More
Patient Square Capital Acquires Nektar Shares Worth $11.96 Million
- New Investment Position: Patient Square Capital LP disclosed in an SEC filing dated May 15, 2026, the purchase of 210,000 shares of Nektar Therapeutics valued at $11.96 million, indicating strong confidence in the biopharmaceutical sector.
- Significant Stake: This acquisition represents 2.68% of Patient Square Capital's reportable AUM, reflecting its emphasis on the future growth potential of Nektar Therapeutics.
- Outstanding Stock Performance: As of May 14, 2026, Nektar's shares were priced at $74.33, up 669.46% year-over-year, significantly outperforming the S&P 500 by 642.16 percentage points, showcasing strong market recognition for its products.
- Successful Clinical Trials: Nektar's rezpegaldesleukin demonstrated impressive results in the Rezolve-AD trial, with many of the 393 patients achieving 75% and 90% skin clearance rates at the 52-week mark, which is expected to propel it into phase 3 studies, enhancing its market outlook.
See More
Nektar Therapeutics to Participate in 2026 Healthcare Conference
- Conference Participation Announcement: Nektar Therapeutics announced its participation in the Jefferies Global Healthcare Conference from June 2-4, 2026, in New York, where management will webcast their session, likely increasing investor interest and enhancing the company's visibility in the biotech sector.
- Webcast Details: The conference webcast will be accessible via the investor events section of the company’s website, with a replay available for 30 days post-event, aimed at fostering investor engagement and enhancing transparency and trust.
- Product Development Progress: Nektar's lead candidate, REZPEG, is undergoing three clinical trials for atopic dermatitis, alopecia areata, and Type 1 diabetes, showcasing the company's potential in treating autoimmune and chronic inflammatory diseases, which may lay the groundwork for future market competitiveness.
- Pipeline Diversity: In addition to REZPEG, Nektar is developing several other candidates, including a preclinical TNFR2 antibody and bispecific programs, indicating a diversified strategy in biopharmaceuticals aimed at addressing the needs of various patient populations.
See More
Nektar to Present at 2026 Jefferies Global Healthcare Conference
- Conference Participation: Nektar Therapeutics will webcast its participation at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 1:20 p.m. Eastern Time, showcasing its latest advancements in treating autoimmune and chronic inflammatory diseases.
- Product Candidate Progress: Nektar's lead product candidate, rezpegaldesleukin (REZPEG), is undergoing three clinical trials, including Phase 2b studies for atopic dermatitis and Type 1 diabetes, highlighting the company's research potential in the biotechnology sector.
- Diverse Clinical Trials: In addition to REZPEG, Nektar is developing a range of candidates, including a bivalent tumor necrosis factor receptor type II antibody and bispecific programs, indicating a broad approach to treating various diseases.
- Investor Interaction Opportunities: During the conference, investors can request one-on-one meetings with company management through their respective representatives, enhancing communication and relationships with stakeholders.
See More
Prosight Management Increases Stake in Nektar Therapeutics
- Share Acquisition: On May 15, 2026, Prosight Management disclosed the purchase of 180,367 shares of Nektar Therapeutics, valued at approximately $10.27 million, indicating strong confidence in the company.
- Increased Ownership: Following this acquisition, Prosight's stake in Nektar accounts for 8.67% of its 13F reportable AUM, highlighting its significance within the investment portfolio.
- Outstanding Stock Performance: As of May 14, 2026, Nektar's stock price stood at $66.61, having surged nearly 600% over the past year, significantly outperforming the S&P 500's 28% increase, reflecting market recognition of its potential.
- Strong Financial Position: Nektar reported first-quarter revenue of $10.9 million, with cash and marketable securities totaling $731.6 million, demonstrating relative strength among clinical-stage biotech peers and enhancing its funding capacity for future development.
See More
Prosight Management Increases Nektar Holdings by $10.27 Million
- Share Increase: Prosight Management increased its holdings in Nektar Therapeutics by 180,367 shares in Q1 2026, representing an estimated $10.27 million investment, reflecting confidence in the company's future.
- Asset Value Growth: The value of Nektar Therapeutics' position rose by $29.43 million during the quarter, driven by both stock price appreciation and the share addition, indicating the company's potential in the biotechnology sector.
- Strong Financial Position: Nektar's revenue increased from $10.5 million to $10.9 million in Q1, with cash and marketable securities totaling $731.6 million, showcasing its competitive edge among clinical-stage biotech firms.
- Clinical Development Outlook: Nektar's rezpegaldesleukin treatment has shown promising data in dermatological conditions, with plans to initiate Phase 3 trials by July, which could significantly enhance the company's valuation if successful.
See More
Prosight Management Increases Stake in Nektar Therapeutics
- Share Increase: On May 15, 2026, Prosight Management disclosed an increase of 180,367 shares in Nektar Therapeutics, valued at approximately $10.27 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The total value of Nektar's shares rose by $29.43 million at the end of the quarter, reflecting the dual impact of trading activity and share price appreciation, further solidifying Prosight's significance in its investment portfolio.
- Improved Financial Position: Nektar's revenue increased from $10.5 million to $10.9 million in the first quarter, with cash and marketable securities reaching $731.6 million, showcasing its relative strength among clinical-stage biotech peers.
- Clinical Development Outlook: Nektar's rezpegaldesleukin treatment has shown encouraging data in trials, with plans to initiate the Phase 3 ZENITH-AD program in July, which could significantly enhance the company's valuation if successful.
See More
Patient Square Capital Acquires Nektar Shares Worth $11.96 Million
- New Investment Position: Patient Square Capital LP disclosed in an SEC filing dated May 15, 2026, the purchase of 210,000 shares of Nektar Therapeutics valued at $11.96 million, indicating strong confidence in the biopharmaceutical sector.
- Significant Stake: This acquisition represents 2.68% of Patient Square Capital's reportable AUM, reflecting its emphasis on the future growth potential of Nektar Therapeutics.
- Outstanding Stock Performance: As of May 14, 2026, Nektar's shares were priced at $74.33, up 669.46% year-over-year, significantly outperforming the S&P 500 by 642.16 percentage points, showcasing strong market recognition for its products.
- Successful Clinical Trials: Nektar's rezpegaldesleukin demonstrated impressive results in the Rezolve-AD trial, with many of the 393 patients achieving 75% and 90% skin clearance rates at the 52-week mark, which is expected to propel it into phase 3 studies, enhancing its market outlook.
See More
